Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RUBY: dostarlimab plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel in advanced or recurrent endometrial cancer
MOH_2019-11-12_007483Phase 3Recruiting
- Sponsor
- TESARO, Inc.
- Start
- Oct 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dostarlimab and niraparib in endometrial cancer (EC) (4 arms), sponsored by TESARO, Inc. Primary endpoints: Efficacy and Safety. Started Oct 2019; status: recruiting.
02
Drugs
dostarlimabniraparib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on MOH_2019-11-12_007483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-11-12_007483.